Literature DB >> 8649060

Epstein-Barr virus in T and natural killer (NK) cell non-Hodgkin's lymphomas.

P Kanavaros1, J Briere, J F Emile, P Gaulard.   

Abstract

Several studies using sensitive in situ hybridization techniques show that, in non-immunocompromised patients, Epstein-Barr virus (EBV) is more frequently detected in lymphomas expressing T cell markers than in B cell lymphomas. Among lymphomas expressing T cell markers, the presence of EBV is highly related to the site of origin of the tumor, being found in nearly all sinonasal lymphomas, in only a proportion of Waldeyer's ring, lung, gastrointestinal and nodal lymphomas, and undetectable in most primary cutaneous lymphomas. The role of EBV in their pathogenesis can be suggested in at least a proportion of extranodal lymphomas (nasal, lung, Waldeyer's ring, gastrointestinal) with T cell markers in which EBV genome is found in most if not all tumor cells (EBV-associated lymphomas) and the transforming LMP-1 protein is frequently expressed. Among these, sinonasal lymphomas constitute a distinct clinicopathologic entity which may present as lethal midline granuloma, are strongly associated with EBV and can be regarded in most cases as true NK cell lymphomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8649060

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Nasal natural killer/T-cell lymphoma and its association with type "i"/XhoI loss strain Epstein-Barr virus in Chile.

Authors:  M E Cabrera; Y Eizuru; T Itoh; C Koriyama; Y Tashiro; S Ding; S Rey; S Akiba; A Corvalan
Journal:  J Clin Pathol       Date:  2006-06-14       Impact factor: 3.411

2.  Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.

Authors:  Li-Min Gao; Sha Zhao; Wen-Yan Zhang; Mi Wang; Hui-Fang Li; Anle Lizaso; Wei-Ping Liu
Journal:  Cancer Biol Ther       Date:  2019-07-16       Impact factor: 4.742

3.  STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.

Authors:  P Coppo; V Gouilleux-Gruart; Y Huang; H Bouhlal; H Bouamar; S Bouchet; C Perrot; V Vieillard; P Dartigues; P Gaulard; F Agbalika; L Douay; K Lassoued; N-C Gorin
Journal:  Leukemia       Date:  2009-05-07       Impact factor: 11.528

4.  Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology.

Authors:  A Chott; W Haedicke; I Mosberger; M Födinger; K Winkler; C Mannhalter; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

5.  Mutational profile and EBV strains of extranodal NK/T-cell lymphoma, nasal type in Latin America.

Authors:  Ivonne A Montes-Mojarro; Bo-Jung Chen; Ana F Ramirez-Ibarguen; Carmen M Quezada-Fiallos; Wendy B Pérez-Báez; Daniela Dueñas; Sandro Casavilca-Zambrano; Marcela Ortiz-Mayor; Erica Rojas-Bilbao; Hernan García-Rivello; Maria F Metrebian; Marina Narbaitz; Carlos Barrionuevo; Carmen Lome-Maldonado; Irina Bonzheim; Falko Fend; Julia Steinhilber; Leticia Quintanilla-Martinez
Journal:  Mod Pathol       Date:  2019-12-10       Impact factor: 7.842

6.  Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.

Authors:  Seungbok Lee; Ha Young Park; So Young Kang; Seok Jin Kim; Jinha Hwang; Seungho Lee; Soo Heon Kwak; Kyong Soo Park; Hae Yong Yoo; Won Seog Kim; Jong-Il Kim; Young Hyeh Ko
Journal:  Oncotarget       Date:  2015-07-10

7.  Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway.

Authors:  Xianxian Sui; Canjing Zhang; Jianan Zhou; Shengxuan Cao; Chen Xu; Feng Tang; Xiuling Zhi; Bobin Chen; Songmei Wang; Lianhua Yin
Journal:  J Exp Clin Cancer Res       Date:  2017-09-26

Review 8.  EBV and the Pathogenesis of NK/T Cell Lymphoma.

Authors:  Ivonne A Montes-Mojarro; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Cancers (Basel)       Date:  2021-03-19       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.